193902-98-6

Basic information

• Product Name: B90114
• Synonyms: 1-Boc-4-(3-amino-4-nitrophenyl)piperazine;B90114
• CAS NO: 193902-98-6
• Molecular Formula: C₁₅H₂₂N₄O₄
• Molecular Weight: 322.363
• Mol File: 193902-98-6.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: B90114(CAS DataBase Reference)
• NIST Chemistry Reference: B90114(193902-98-6)
• EPA Substance Registry System: B90114(193902-98-6)

Safety Data

• Hazardous Substances Data: 193902-98-6(Hazardous Substances Data)

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 127-19-5 N,N-dimethyl acetamide 

Downstream Products

• 668432-44-8 4-amino-5-fluoro-3-(6-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one 
• 1820703-82-9 tert-butyl 4-(4-bromo-3-chlorophenyl)piperazine-1-carboxylate 
• 1386950-73-7 tert-butyl 4-(4-amino-3-chlorophenyl)piperazine-1-carboxylate 
• 1621399-60-7 C₁₉H₁₉FN₆O 
• 1621399-82-3 tert-butyl 4-(2-(2-amino-5-fluorophenylcarbamoyl)quinoxalin-6-yl)piperazine-1-carboxylate 
• 1621399-59-4 C₁₉H₁₉FN₆O 
• 1621399-81-2 tert-butyl 4-(2-(2-(tert-butoxycarbonylamino)-4-fluorophenylcarbamoyl)-quinoxalin-6-yl)-piperazine-1-carboxylate 
• 1339046-76-2 4-[2-(3,4-diamino-phenyl)-1H-benzoimidazol-5-yl]-piperazine-1-carboxylic acid dimethylamide 
• 1339046-74-0 4-[2-(4-amino-3-nitro-phenyl)-1H-benzoimidazol-5-yl]-piperazine-1-carboxylic acid dimethylamide 
• 1339046-72-8 4-(3-amino-4-nitro-phenyl)-piperazine-1-carboxylic acid dimethylamide 
• 96103-52-5 2-nitro-5-piperazin-1-yl-phenylamine 
• 193902-99-7 tert-butyl 4-(3,4-diaminophenyl)piperazine-1-carboxylate 
• 885232-22-4 4-[4-nitro-3-(2-phenoxy-acetylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: A way forward for targeting hypoxia and drug resistance of cancer cells

To establish a new approach for the synthesis of quinoxaline 1,4-dioxides as hypoxia-selective cytotoxic agents, an original multi-step preparation of derivatives possessing the diamine moiety at position 7 was evaluated. Herein, we present the synthesis of a series of novel 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides 13a-h, 14a,b,g based on the regioselective Beirut reaction. Comparison of antitumor properties of derivatives possessing the diamine moiety at position 7 with structurally close congeners possessing the corresponding amino groups at position 6 revealed key differences in the cytotoxicity profiles and HIF-1α inhibition. All the synthesized 7-amino-6-halogeno derivatives 13a-h, 14a,b,g demonstrated significant cytotoxic activities against breast cancer cell lines (MCF7, MDA-MB-231) in normoxia and hypoxia with IC50 values ranging from 0.1 to 7.6 μM. Most of these novel derivatives can circumvent the multidrug resistance of tumor cells caused by P-glycoprotein over expression. The lead compounds 13a, 14a and 14b can suppress the expression of HIF-1α at low micromolar concentrations and induce apoptosis in breast cancer MCF7 cells. In addition, compound 14b effectively inhibits BCL2 and ERα expression in MCF7 cells. The current research opens a new direction for targeting hypoxia and drug resistance of cancer cells. This journal is

Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells

Acute myeloid leukemia (AML) refers to one of the most lethal blood malignancies worldwide. FLT3-ITD mutation is recognized as the most common one that predicted a poorer prognosis. There have been many prominent FLT3-ITD inhibitors approved by the FDA for clinical therapies. However, as impacted by undesirable off-target effects, differentiated metabolic issues, and clinical drug resistance problems, it remains challenging to discover alternative and promising solutions for treating FLT3-ITD+ AML. In this study, dovitinib was chemically modified and converted into CRBN-recruiting PROTACs. Two active compounds were identified, which showed enhanced antiproliferative effects against FLT3-ITD+ AML cells, both in vitro and in vivo. As demonstrated from further biological evaluation, the compounds could induce the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely block their downstream signaling pathway. The findings of this study would provide another promising strategy to develop novel therapies for FLT3-ITD+ AML.

HETEROCYCLIC COMPOUNDS

The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.